Morphine promotes renal pathology in sickle mice

Marc L. Weber, Derek Vang, Paulo E. Velho, Pankaj Gupta, John T Crosson, Robert P Hebbel, Kalpna Gupta

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Patients with sickle cell disease (SCD) are often treated with opioids for severe pain. Although opioids are known to have renal-specific effects, their role in nephropathy in SCD remains unknown. Because a subset of patients receives opioids for long periods of time, we examined the influence of chronic morphine treatment on mice with pre-existing renal disease expressing varying amounts of sickle hemoglobin. Morphine treatment for 3-6 weeks resulted in a variety of defects in renal morphology observed using light and electron microscopy. Notably, morphine induced glomerular pathology, resulting in increased glomerular volume, mesangial expansion, mesangial cell proliferation, parietal cell metaplasia, podocyte effacement, and microvillus transformation. Cystic tubulopathy and hemeoxygenase-1 expression and activity were also increased in morphine-treated mice. Naloxone, a non-selective opioid receptor (OR) antagonist, ameliorated these effects. Functionally, the urine albumin to creatinine ratio was increased following acute as well as chronic morphine treatment. These results suggest that clinically relevant doses of morphine induce renal pathology and that OR antagonists may be effective for ameliorating morphine-induced renal disease.

Original languageEnglish (US)
Pages (from-to)109-118
Number of pages10
JournalInternational Journal of Nephrology and Renovascular Disease
StatePublished - Jul 19 2012


  • Mesangial cell
  • Morphine
  • Nephropathy
  • Pain
  • Podocyte
  • Sickle cell disease


Dive into the research topics of 'Morphine promotes renal pathology in sickle mice'. Together they form a unique fingerprint.

Cite this